Prime Medicine Shares Hit 52-Week High After Dosing Begins in PM577a Trial
By Chris Wack
Prime Medicine shares rose after the company said the first patient has been dosed in a Phase 1/2 clinical trial of PM577a, an investigational in vivo prime editor for H1069Q-mutated Wilson disease.
The stock was 21% higher, at $5.27, on Wednesday, just off its 52-week high earlier in the session.
The biotechnology company said the milestone marks the first clinical evaluation of its liver franchise.
The company also announced that the Food and Drug Administration has granted rare pediatric disease designation to PM577 for Wilson disease.
The Phase 1/2 clinical trial is an open-label, global, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of PM577a in adults and adolescents with Wilson disease containing at least one p.H1069Q allele in the ATP7B gene.
The company said the study will initially enroll adults who are clinically stable on standard-of-care therapy.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 28, 2026 14:08 ET (18:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
There Are Three Paths Forward for the AI Boom. Two of Them Lead to Lower Interest Rates
United States